Genetic Technologies Limited
GENE
$0.765
-$0.015-1.92%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -7.88M | -8.14M | -8.44M | -8.15M | -7.91M |
| Total Depreciation and Amortization | 350.80K | 382.70K | 417.50K | 434.60K | 455.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 994.90K | 2.11M | 3.25M | 2.23M | 1.19M |
| Change in Net Operating Assets | 181.40K | -42.30K | -268.90K | -268.90K | -268.90K |
| Cash from Operations | -6.35M | -5.68M | -5.05M | -5.76M | -6.54M |
| Capital Expenditure | -21.60K | -24.80K | -28.10K | -19.90K | -11.80K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 0.00 | 0.00 | -159.90K | -326.10K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 96.70K | 124.30K | 152.90K | 140.60K | 129.20K |
| Cash from Investing | 75.20K | 99.60K | 124.80K | -39.20K | -208.70K |
| Total Debt Issued | 601.00K | 300.50K | -- | -- | -- |
| Total Debt Repaid | -348.80K | -345.80K | -342.80K | -339.60K | -336.40K |
| Issuance of Common Stock | 2.58M | 4.87M | 7.17M | 7.17M | 7.17M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.80K | -462.50K | -918.20K | -917.10K | -916.00K |
| Cash from Financing | 1.86M | 2.90M | 4.00M | 4.00M | 4.00M |
| Foreign Exchange rate Adjustments | -58.30K | 33.90K | 127.70K | 143.00K | 158.60K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.48M | -2.65M | -796.70K | -1.65M | -2.59M |
